{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:22:17Z","timestamp":1790036537495,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.clinthera.2017.01.001","type":"journal-article","created":{"date-parts":[[2017,1,28]],"date-time":"2017-01-28T06:15:51Z","timestamp":1485584151000},"page":"370-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation"],"prefix":"10.1016","volume":"39","author":[{"given":"Francesco","family":"Scaglione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaantanu","family":"Donde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek A.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuele A.","family":"Jannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.01.001_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"Impotence. NIH Consensus Development Panel on Impotence","volume":"270","year":"1993","journal-title":"Jama"},{"key":"10.1016\/j.clinthera.2017.01.001_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1046\/j.1464-410x.1999.00142.x","article-title":"The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences","volume":"84","author":"Ayta","year":"1999","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2017.01.001_bib3","first-page":"83","article-title":"Evaluation and management of erectile dysfunction in clinical practice","volume":"16","author":"Brant","year":"2009","journal-title":"JCOM"},{"key":"10.1016\/j.clinthera.2017.01.001_bib4","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/jsm.12068","article-title":"A systematic review assessing the economic impact of sildenafil citrate (Viagra) in the treatment of erectile dysfunction","volume":"10","author":"Martin","year":"2013","journal-title":"J Sex Med"},{"key":"10.1016\/j.clinthera.2017.01.001_bib5","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/j.1743-6109.2009.01601.x","article-title":"Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS)","volume":"7","author":"Corona","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.clinthera.2017.01.001_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amjmed.2006.06.010","article-title":"Prevalence and risk factors for erectile dysfunction in the US","volume":"120","author":"Selvin","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2017.01.001_bib7","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/S0022-5347(05)64302-9","article-title":"Psychological impact of erectile dysfunction: validation of a new health related quality of life measure for patients with erectile dysfunction","volume":"168","author":"Latini","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2017.01.001_bib8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/00926230490262366","article-title":"Impact of erectile dysfunction (ED) on sexual life of female partners: assessment with the Index of Sexual Life (ISL) questionnaire","volume":"30","author":"Chevret","year":"2004","journal-title":"J Sex Marital Ther"},{"key":"10.1016\/j.clinthera.2017.01.001_bib9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0090-4295(02)01606-0","article-title":"Quality of life and erectile dysfunction","volume":"59","author":"Althof","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2017.01.001_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.bbrc.2006.01.035","article-title":"Subcellular localization and regulation of type-1C and type-5 phosphodiesterases","volume":"341","author":"Dolci","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"suppl 3","key":"10.1016\/j.clinthera.2017.01.001_bib11","first-page":"S26","article-title":"Four-year review of sildenafil citrate","volume":"4","author":"McCullough","year":"2002","journal-title":"Rev Urol"},{"key":"10.1016\/j.clinthera.2017.01.001_bib12","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2147\/PPA.S56002","article-title":"A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil","volume":"9","author":"Evans","year":"2015","journal-title":"Patient Pref Adher"},{"key":"10.1016\/j.clinthera.2017.01.001_bib13","doi-asserted-by":"crossref","first-page":"I14","DOI":"10.1002\/clc.4960271305","article-title":"Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles","volume":"27","author":"Seftel","year":"2004","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.clinthera.2017.01.001_bib14","first-page":"99","article-title":"Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil","volume":"3","author":"Raheem","year":"2009","journal-title":"Patient Pref Adher"},{"key":"10.1016\/j.clinthera.2017.01.001_bib15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1590\/S1677-5538.IBJU.2014.03.14","article-title":"PDE5 inhibitor treatment persistence and adherence in Brazilian men: post-hoc analyses from a 6-month, prospective, observational study","volume":"40","author":"Cairoli","year":"2014","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.clinthera.2017.01.001_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1743-6109.2011.02611.x","article-title":"How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors","volume":"9","author":"Jannini","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.clinthera.2017.01.001_bib17","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.eururo.2013.01.012","article-title":"Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis","volume":"63","author":"Yuan","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clinthera.2017.01.001_bib18","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1743-6109.2009.01375.x","article-title":"The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction","volume":"6","author":"Jannini","year":"2009","journal-title":"J Sex Med"},{"key":"10.1016\/j.clinthera.2017.01.001_bib19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14740338.2016.1130126","article-title":"The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis","volume":"15","author":"Corona","year":"2016","journal-title":"Expert Opin drug saf"},{"key":"10.1016\/j.clinthera.2017.01.001_bib20","first-page":"701","article-title":"Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility","volume":"10","author":"Katz","year":"2014","journal-title":"Ther Clin risk Manage"},{"key":"10.1016\/j.clinthera.2017.01.001_bib21","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1210\/en.2003-1699","article-title":"Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa","volume":"145","author":"Morelli","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2017.01.001_bib22","unstructured":"Sildenafil 25mg, 50mg and 100 mg film-coated tablet. Summary of product characteristics (SPC) - (Emc). Medicines.org.uk. 2016."},{"key":"10.1016\/j.clinthera.2017.01.001_bib23","series-title":"Levitra (vardenafil hydrochloride) [package insert]","year":"2015"},{"key":"10.1016\/j.clinthera.2017.01.001_bib24","unstructured":"Stendra (Avanafil) [package insert]. Mountain View, CA: Vivus Inc: 2015."},{"key":"10.1016\/j.clinthera.2017.01.001_bib25","unstructured":"Viagra (Sildenafil citrate) [package insert]. New York, NY: Pfizer Inc; 2015."},{"key":"10.1016\/j.clinthera.2017.01.001_bib26","unstructured":"Cialis (tadalafil) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2016."},{"key":"10.1016\/j.clinthera.2017.01.001_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1161\/CIRCULATIONAHA.110.944603","article-title":"Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension","volume":"122","author":"Schwartz","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2017.01.001_bib28","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clinthera.2013.12.010","article-title":"Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects","volume":"36","author":"Damle","year":"2014","journal-title":"Clin Ther"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2017.01.001_bib29","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1046\/j.0306-5251.2001.00027.x","article-title":"Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality","volume":"53","author":"Nichols","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.01.001_bib30","first-page":"46","article-title":"Formulation of new sildenafil citrate-caffeine orally disintegrating tablets: in vitro and in vivo evaluation","volume":"3","author":"Halim","year":"2013","journal-title":"J Pharma Res Opin"},{"issue":"suppl 5A","key":"10.1016\/j.clinthera.2017.01.001_bib31","first-page":"44s","article-title":"Management of acid-related disorders in patients with dysphagia","volume":"117","author":"Howden","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2017.01.001_bib32","first-page":"56","article-title":"Formulation and evaluation of fast dissolving tablet of sildenafil citrate","volume":"6","author":"Singh VK","year":"2014","journal-title":"Der Pharmacia Lettre"},{"key":"10.1016\/j.clinthera.2017.01.001_bib33","unstructured":"Levitra 5mg, 10mg and 20 mg film-coated tablet Summary of product characteristics (SPC) - (Emc). Medicines.org.uk. 2013."},{"key":"10.1016\/j.clinthera.2017.01.001_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.5414\/CP201995","article-title":"Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water","volume":"52","author":"Kim","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2017.01.001_bib35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.clinthera.2013.02.006","article-title":"Pharmacokinetic comparison of an orally disintegrating film formulation with a film-coated tablet formulation of sildenafil in healthy Korean subjects: a randomized, open-label, single-dose, 2-period crossover study","volume":"35","author":"Roh","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.01.001_bib36","first-page":"112","article-title":"Formulation and evaluation of oral fast dissolving tablets of sildenafil citrate","volume":"3","author":"Sivakranth","year":"2011","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1016\/j.clinthera.2017.01.001_bib37","doi-asserted-by":"crossref","first-page":"530","DOI":"10.5414\/CP202073","article-title":"Pharmacokinetics and bioequivalence of sildenafil granules and sildenafil tablets in Korean healthy volunteers","volume":"52","author":"Zheng","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2017.01.001_bib38","first-page":"203","article-title":"A review on techniques for oral bioavailability enhancement of drugs","volume":"4","author":"Hetal","year":"2010","journal-title":"Int J Pharmaceutical Sci Rev Res"},{"key":"10.1016\/j.clinthera.2017.01.001_bib39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/PPA.S14030","article-title":"Orally disintegrating vardenafil tablets for the treatment of erectile dysfunction: efficacy, safety, and patient acceptability","volume":"5","author":"Green","year":"2011","journal-title":"Patient Pref Adher"},{"key":"10.1016\/j.clinthera.2017.01.001_bib40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/jsm.12344","article-title":"Health-related characteristics and unmet needs of men with erectile dysfunction: a survey in five European countries","volume":"11","author":"Jannini","year":"2014","journal-title":"J Sex Med"},{"key":"10.1016\/j.clinthera.2017.01.001_bib41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/sj.sc.3101011","article-title":"Quality of life in patients with spinal cord injury receiving Viagra (sildenafil citrate) for the treatment of erectile dysfunction","volume":"38","author":"Hultling","year":"2000","journal-title":"Spinal Cord"},{"key":"10.1016\/j.clinthera.2017.01.001_bib42","unstructured":"Levitra 5 mg, 10 mg and 20 mg film-coated tablet Summary of product characteristics (SPC) - (Emc). Medicines.org.uk. 2016."},{"key":"10.1016\/j.clinthera.2017.01.001_bib43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/11584950-000000000-00000","article-title":"Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: results of three clinical trials","volume":"31","author":"Heinig","year":"2011","journal-title":"Clin Drug Investig"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817300024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817300024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T19:58:08Z","timestamp":1536091088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817300024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0149291817300024"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.01.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}